112 related articles for article (PubMed ID: 28691251)
21. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.
Mendes D; Alves C; Batel Marques F
Expert Opin Drug Saf; 2016 Oct; 15(10):1301-12. PubMed ID: 27467204
[TBL] [Abstract][Full Text] [Related]
22. Drug-associated cardiovascular risks: A retrospective evaluation of withdrawn drugs.
Kocadal K; Saygi S; Alkas FB; Sardas S
North Clin Istanb; 2019; 6(2):196-202. PubMed ID: 31297490
[TBL] [Abstract][Full Text] [Related]
23. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
Olivier P; Montastruc JL
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
[TBL] [Abstract][Full Text] [Related]
24. [Vigilance for veterinary medicinal products: declarations of adverse reactions in the year 2010].
Müntener CR; Bruckner L; Stürer A; Althaus FR; Caduff-Janosa P
Schweiz Arch Tierheilkd; 2012 Feb; 154(2):57-65. PubMed ID: 22287137
[TBL] [Abstract][Full Text] [Related]
25. How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009.
Lexchin J
Open Med; 2014; 8(1):e14-9. PubMed ID: 25009681
[TBL] [Abstract][Full Text] [Related]
26. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
27. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
[TBL] [Abstract][Full Text] [Related]
28. [Vigilance for veterinary medicinal products: declarations of suspected adverse reactions in the year 2007].
Müntener CR; Bruckner L; Stürer A; Althaus FR; Schneider A
Schweiz Arch Tierheilkd; 2009 Jan; 151(1):12-20. PubMed ID: 19160166
[TBL] [Abstract][Full Text] [Related]
29. [Safety of medicinal products and reporting of adverse drug reactions].
Skibicka I; Maciejczyk A
Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
[TBL] [Abstract][Full Text] [Related]
30. Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy.
Lexchin J
Br J Clin Pharmacol; 2015 May; 79(5):847-59. PubMed ID: 25393960
[TBL] [Abstract][Full Text] [Related]
31. WITHDRAWN--a resource for withdrawn and discontinued drugs.
Siramshetty VB; Nickel J; Omieczynski C; Gohlke BO; Drwal MN; Preissner R
Nucleic Acids Res; 2016 Jan; 44(D1):D1080-6. PubMed ID: 26553801
[TBL] [Abstract][Full Text] [Related]
32. Drug safety: withdrawn medications are only part of the picture.
Rawson NS
BMC Med; 2016 Feb; 14():28. PubMed ID: 26873482
[TBL] [Abstract][Full Text] [Related]
33. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
34. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
35. Adverse drug reactions: definitions, diagnosis, and management.
Edwards IR; Aronson JK
Lancet; 2000 Oct; 356(9237):1255-9. PubMed ID: 11072960
[TBL] [Abstract][Full Text] [Related]
36. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009.
Qureshi ZP; Seoane-Vazquez E; Rodriguez-Monguio R; Stevenson KB; Szeinbach SL
Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):772-7. PubMed ID: 21574210
[TBL] [Abstract][Full Text] [Related]
37. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products.
Cavagnaro J; Silva Lima B
Eur J Pharmacol; 2015 Jul; 759():51-62. PubMed ID: 25814257
[TBL] [Abstract][Full Text] [Related]
38. Drug-induced ocular adverse reactions: review of the safety alerts issued during the last decade.
Penedones A; Mendes D; Alves C; Marques FB
J Ocul Pharmacol Ther; 2015 Jun; 31(5):258-68. PubMed ID: 25871404
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
40. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
